Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India

View Full Paper
Ask AI
Bookmark
Share

Authors

PSParas SatadeveAGAdamya GuptaSSSashi Singh

Discussion

Loading...

Member takes

Overview

Real-world data reveals early bone marrow response in newly diagnosed AML patients treated with venetoclax and decitabine, suggesting effective treatment management.

Key Points

  • This research aims to evaluate early bone marrow assessment and treatment outcomes in AML patients treated with venetoclax plus decitabine.
  • Evaluated early bone marrow response at day 14 of treatment with venetoclax and decitabine in newly diagnosed AML patients.
  • Assessed measurable residual disease using flowcytometric analysis after two cycles of therapy.
  • Conducted genetic testing for abnormalities in the patient cohort.
  • 22% of evaluable patients had marrow blasts <5% at day 14 of therapy.
  • 46% of patients achieved CR or CRi after two cycles, and 38% achieved MRD negative status after cycle 2.
  • Median overall survival was 17 months, with significant myelosuppression reported.

Cite This Study

Satadeve et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d554https://doi.org/10.1182/blood-2025-7043
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial2025 · 1 citations
  2. 2Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS2025
  3. 3Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia2025 · 1 citations
  4. 4Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in De Novo AML2026
  5. 5Efficacy of a 14-day venetoclax regimen in combination with a hypomethylating agent for Acute Myeloid Leukemia: A single-center retrospective analysis2025